Key PointsQuestion
Is intravenous administration of tranexamic acid associated with thromboembolic events in patients of all ages and of any medical discipline?
Findings
In this systematic review and meta-analysis of 216 studies of 125 550 patients undergoing surgical procedures and receiving either intravenous administration of tranexamic acid or placebo or no treatment, 1020 (2.1%) thromboembolic events in the tranexamic acid group and 900 (2.0%) total thromboembolic events in the control group were found. There was no increased risk of any thromboembolic event in patients of all medical disciplines.
Meaning
These results clarify whether vascular occlusive events are associated with administration of tranexamic acid.
Importance
Tranexamic acid (TXA) is an efficient antifibrinolytic agent; however, concerns remain about the potential adverse effects, particularly vascular occlusive events, that may be associated with its use.
Objective
To examine the association between intravenous TXA and total thromboembolic events (TEs) and mortality in patients of all ages and of any medical disciplines.
Data Source
Cochrane Central Register of Controlled Trials and MEDLINE were searched for eligible studies investigating intravenous TXA and postinterventional outcome published between 1976 and 2020.
Study Selection
Randomized clinical trials comparing intravenous TXA with placebo/no treatment. The electronic database search yielded a total of 782 studies, and 381 were considered for full-text review. Included studies were published in English, German, French, and Spanish. Studies with only oral or topical tranexamic administration were excluded.
Data Extraction and Synthesis
Meta-analysis, subgroup and sensitivity analysis, and meta-regression were performed. This study followed the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) reporting guideline.
Main Outcomes and Measures
Vascular occlusive events and mortality.
Results
A total of 216 eligible trials including 125 550 patients were analyzed. Total TEs were found in 1020 (2.1%) in the group receiving TXA and 900 (2.0%) in the control group. This study found no association between TXA and risk for total TEs (risk difference = 0.001; 95% CI, −0.001 to 0.002; P = .49) for venous thrombosis, pulmonary embolism, venous TEs, myocardial infarction or ischemia, and cerebral infarction or ischemia. Sensitivity analysis using the risk ratio as an effect measure with (risk ratio = 1.02; 95% CI, 0.94-1.11; P = .56) and without (risk ratio = 1.03; 95% CI, 0.95-1.12; P = .52) studies with double-zero events revealed robust effect size estimates. Sensitivity analysis with studies judged at low risk for selection bias showed similar results. Administration of TXA was associated with a significant reduction in overall mortality and bleeding mortality but not with nonbleeding mortality. In addition, an increased risk for vascular occlusive events was not found in studies including patients with a history of thromboembolism. Comparison of studies with sample sizes of less than or equal to 99 (risk difference = 0.004; 95% CI, −0.006 to 0.014; P = .40), 100 to 999 (risk difference = 0.004; 95% CI, −0.003 to 0.011; P = .26), and greater than or equal to 1000 (risk difference = −0.001; 95% CI, −0.003 to 0.001; P = .44) showed no association between TXA and incidence of total TEs. Meta-regression of 143 intervention groups showed no association between TXA dosing and risk for venous TEs (risk difference, −0.005; 95% CI, −0.021 to 0.011; P = .53).
Conclusions and Relevance
Findings from this systematic review and meta-analysis of 216 studies suggested that intravenous TXA, irrespective of dosing, is not associated with increased risk of any TE. These results help clarify the incidence of adverse events associated with administration of intravenous TXA and suggest that TXA is safe for use with undetermined utility for patients receiving neurological care.
Major surgery is commonly associated with substantial blood loss, subsequent anemia, and the need for blood transfusion. The Vascular Events in Noncardiac Surgery Patients Cohort Evaluation (VISION) study investigators1 reported that among 40 004 patients undergoing noncardiac surgical procedures, the most common complications leading to death were major bleeding followed by myocardial injury and infection. Tranexamic acid (TXA) is an antifibrinolytic agent and widely used for prophylaxis and treatment of bleeding caused by hyperfibrinolysis. Poeran and colleagues2 reported that the use of TXA increased in orthopedic surgery from almost 0% in 2006 to 11.2% in 2012, and the effectiveness to reduce surgical blood loss and associated complications has been reported.
Ker and colleagues3 performed a meta-analysis including 129 trials encompassing more than 10 000 patients suggesting that administration of TXA is associated with reductions in allogeneic blood transfusion by 38% and that further trials assessing this effect are unlikely to add new insights. However, TXA is only applied with caution because antifibrinolytic therapy may be associated with an increased risk of seizures,4,5 myocardial infarction,6 and other thrombotic complications.7-9 Nevertheless, the association of vascular occlusive events with TXA administration is controversial. Quiz Ref IDOverall, vascular occlusive events are rare, and studies with 0 events are often excluded from meta-analysis because the assumption is that these studies may not be relevant to the treatment effect. Of 115 investigated trials in the meta-analysis by Ker and colleagues,3 72 examined the rate of pulmonary embolism (PE) and 66 studies examined the rate of deep vein thrombosis (DVT). However, trials with 0 events were excluded from analysis. Overall, TXA was not associated with an increased risk of PE in 10 trials (risk ratio [RR] = 0.61; 95% CI, 0.25-1.47) (event rate in TXA group: 4 of 449 vs control: 8 of429) and DVT in 19 trials (RR = 0.86; 95% CI, 0.53-1.39) (event rate in TXA group: 25 of 785 vs control: 29 of 785). Based on the low number of included event rates, the issue of use of TXA and vascular occlusive events remains unaddressed.3 Several guidelines recommend the use of TXA in patients with excessive bleeding.10-13 However, little is known about the incidence of vascular occlusive events in patients with substantial comorbidities or a history of thromboembolic events (TEs). In addition, debate is ongoing about the optimal perioperative dosing of intravenous TXA, which varies widely, ranging from 0.5 to 5 g or 10 to 100 mg/kg and might also explain the different observed incidences of vascular occlusive events.
To further explore the possible associations between intravenous TXA and vascular occlusive events in patients undergoing surgery or experiencing bleeding, we performed a comprehensive meta-analysis. Quiz Ref IDWe included randomized clinical trials (RCTs) irrespective of event rate and dosing regimen comparing intravenous TXA with a control group (placebo or no treatment) in our analysis. These data might help to clarify the safety of intravenous TXA and elucidate a possible dosing effect.
Search Strategy and Study Selection
We systematically searched Cochrane Central Register of Controlled Trials and MEDLINE via PubMed for eligible RCTs investigating the effect of intravenous TXA on postinterventional outcome published between 1976 and 2018, followed by a manual search through September 20, 2019. To identify RCTs published after completion of the meta-analysis, another systematic review was performed for eligible studies published between July 1, 2018, and December 31, 2020. Search terms used and additional details are available in eAppendix 1 in the Supplement.
End points were venous thrombosis (VT), PE, venous thromboembolic events (VTEs), myocardial infarction or ischemia (MI), cerebral infarction or ischemia (CII), limb ischemia, mesenteric ischemia, hepatic artery thrombosis, and composite of all vascular occlusive events (total thromboembolic events [total TEs]). In addition, we assessed overall mortality, bleeding mortality, and any nonbleeding mortality rate (eAppendix 2 in the Supplement).
Data Extraction and Statistical Analyses
This study was conducted in accordance with the recommendations of the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) reporting guideline for cohort studies.14 Because many studies showed 0 events in both groups, we assessed the risk difference (RD) to provide accurate results. The fixed-effect analysis was used for meta-analysis because we assumed that the true effect size was the same in all studies because TEs are rare and the only reason the effect size varied between studies could be caused by the number of recruited patients. However, we performed sensitivity analysis using a random-effects model to estimate whether our results were robust. Furthermore, we performed a sensitivity analysis using the RR as an effect size measure with either including (continuity correction of 0.5) or excluding studies with 0 cell frequencies. An additional analysis of total TEs with subgroups by study size was conducted. Heterogeneity was assessed by using I2 statistics. A meta-regression was performed to investigate a relation between the event rate and the dosage of intravenous TXA.
We also investigated whether intravenous TXA was associated with increased risk for TE, VT, PE, VTEs, and overall mortality in patients with risks for TEs. Therefore, secondary analyses were performed only with studies including patients with a history of any TE, coronary artery disease, thrombophilia, or contraindication for TXA. Two of us (I.T. and S.C.) independently assessed the methodologic quality of included studies based on the Cochrane Risk of Bias tool. A sensitivity analysis with studies judged at low risk of selection bias was assessed for total TEs. Funnel plots were generated to detect possible evidence for small-study bias. Discrepancies were resolved by group discussion (I.T., S.C., P.M., E.H., and S.W.). Two-sided P < .05 was considered statistically significant. The Review Manager (RevMan) program, version 5.3 (The Nordic Cochrane Centre) and R software, version 3.6.1 (R Foundation for Statistical Computing) were used for analysis and graphic illustrations. Continuity corrections were performed with the R package, meta version 4.12-0. Further details appear in eAppendix 3 in the Supplement.
The electronic database and manual search yielded a total of 782 studies published between 1976 and 2018. In total, 381 articles were considered for full-text review, of which 189 were excluded because of ineligible study designs (n = 55) or control groups (n = 92), ineligible end points (n = 27), missing or nontranslatable full text (n = 11), and duplicates (n = 4), leaving 192 RCTs6,15-205 for final analysis (Figure). Included studies were published in English, German, French, and Spanish. Twenty-three authors were contacted, of whom 2 provided clarification113 or data,185 whereas 21 did not reply. In total, 68 118 patients of this search were included in this meta-analysis (34 610 TXA group and 33 508 control group). Demographic data and subgroup characteristics are reported in eTable 1 and eAppendix 4 in the Supplement.
Total Thromboembolic Events
In total, 176 studies (eAppendix 11 in the Supplement) provided data on total TEs in 65 900 patients (n = 33 487 TXA group vs n = 32 413 control group). We found 779 total TEs (2.3%) in the TXA group and 706 total TEs (2.2%) in the control group. Quiz Ref IDOverall, administration of intravenous TXA was not associated with an increased risk for total TEs (RD = 0.001; 95% CI, −0.002 to 0.003; P = .66) (Table 1; eFigure 1 in the Supplement). However, the subgroup analysis showed that TXA was associated with a significantly increased risk for total TEs in the group of patients with neurological conditions (RD = 0.026; 95% CI, 0.007-0.045; P = .007). Sensitivity analysis using a random-effects model showed robust effect estimates for total TEs (RD = −0.001; 95% CI, −0.002 to 0.001; P = .39), but no significantly increased risk for total TEs in the subgroup of patients with neurological conditions was shown (RD = 0.018; 95% CI, −0.013 to 0.048; P = .26) (Table 1; eFigure 2 in the Supplement). Analysis of patients with neurological conditions showed a significant heterogeneity (I2 = 57%). To investigate whether the heterogeneity was associated with sample size, we performed a sensitivity analysis including studies with sample sizes with more than 1000 patients. Overall, the heterogeneity remained high (I2 = 73%). A sensitivity analysis was performed using the RR as an effect measure with and without studies with double-zero events revealed robust effect estimates for all subgroups (RR = 1.01; 95% CI, 0.92-1.11; P = .77 and RR = 1.02; 95% CI, 0.93-1.12; P = .71) (eFigure 3 and eFigure 4 in the Supplement). To elucidate whether incidence of total TEs increases with sample size, we performed a sensitivity analysis of studies including less than or equal to 99 patients, 100 to 999 patients, or greater than or equal to 1000 patients. Overall, administration of intravenous TXA was not associated with an increased risk for total TEs in studies with less than or equal to 99 patients (RD = 0.004; 95% CI, −0.006 to 0.014; P = .40), 100 to 999 patients (RD = 0.004; 95% CI, −0.003 to 0.011; P = .26), and greater than or equal to 1000 patients (RD = −0.001; 95% CI, −0.003 to 0.001; P = .44) (eFigure 5 in the Supplement). The results remained robust using a random-effects model (eFigure 6 in the Supplement).
Venous Thrombosis, Pulmonary Embolism, and Venous Thromboembolic Events
In total, 163 studies (eAppendix 12 in the Supplement) provided data on VTs in 59 666 patients (n = 30 334 TXA group vs n = 29 332 control group). We found 272 VTs (0.9%) in the TXA group and 213 VTs (0.7%) in the control group. Quiz Ref IDOverall, administration of intravenous TXA was not associated with an increased risk for VT (RD = −0.000; 95% CI, −0.002 to 0.002; P > .99) (eTable 2, eFigure 7 in the Supplement). Sensitivity analysis using a random-effects model showed robust effect estimates for PE (RD = −0.000; 95% CI, −0.001 to 0.000; P = .26) (eTable 2; eFigure 8 in the Supplement).
In total, 129 studies (eAppendix 13 in the Supplement) provided data on PE events in 61 562 patients (n = 31 155 TXA group vs n = 30 407 control group). We found 152 PE events (0.5%) in the TXA group and 153 PE events (0.5%) in the control group. Overall, administration of intravenous TXA was not associated with an increased risk for PE (RD = −0.000; 95% CI, −0.001 to 0.001; P = .89) (eTable 3; eFigure 9 in the Supplement). Sensitivity analysis using a random-effects model showed robust effect estimates for VT (RD = −0.000; 95% CI, −0.001 to 0.001; P = .68) (eTable 3; eFigure 10 in the Supplement).
To assess the total number of VTEs, PE and VT were combined and analyzed. In total, 123 studies (eAppendix 14 in the Supplement) provided data on VTEs in 56 126 patients (n = 28 438 TXA group vs n = 27 688 control group). We found 348 VTEs (1.2%) in the TXA group and 304 VTEs (1.1%) in the control group. Overall, administration of intravenous TXA was not associated with an increased risk for VTEs (RD = −0.000; 95% CI, −0.002 to 0.002; P = .71) (eTable 4; eFigure 11 in the Supplement). Sensitivity analysis using a random-effects model showed robust effect estimates for VTE (RD = −0.001; 95% CI, −0.002 to 0.001; P = .39) (eTable 4; eFigure 12 in the Supplement).
Myocardial Infarction or Ischemia, Cerebral Infarction or Ischemia, and Other Thromboembolic Events
Overall, administration of intravenous TXA was not associated with an increased risk for MI (RD = −0.000; 95% CI, −0.001 to 0.001; P = .56) (eTable 5; eFigure 13 and eFigure 14 in the Supplement). Detailed analyses are reported in eAppendix 5 in the Supplement.
Overall, administration of intravenous TXA was not associated with an increased risk for CII (RD = −0.000; 95% CI, −0.001 to 0.000; P = .90) (eTable 6; eFigure 15 in the Supplement) or other TEs (eFigures 16-18 in the Supplement). Detailed analyses are reported in eAppendix 6 in the Supplement.
In total, 63 studies (eAppendix 15 in the Supplement) assessed the overall mortality in 55 305 patients (n = 27 865 TXA group vs n = 27 440 control group). Death occurred in 2218 patients (8%) in the TXA group and 2456 patients (9%) in the control group. Overall, administration of intravenous TXA was associated with significant reductions in overall mortality in patients of the TXA group (RD = −0.011; 95% CI, −0.015 to −0.007; P < .001) (Table 2) (eFigure 19 in the Supplement). Subgroup analysis showed a significantly decreased overall mortality in patients with trauma (RD = −0.015; 95% CI, −0.022 to −0.008; P = .004) and patients receiving care from other disciplines (RD = −0.038; 95% CI, −0.06 to −0.015; P = .001) for the TXA groups, whereas no significant differences could be detected within the remaining medical disciplines. Sensitivity analysis using a random-effects model did not show robust effect estimates for overall mortality (RD = −0.004; 95% CI, −0.008 to 0.000; P = .05) and for the subgroup of patients receiving care from other disciplines (RD = −0.024; 95% CI, −0.058 to 0.009; P = .15) (Table 2; eFigure 20 in the Supplement). Analysis of patients of other disciplines showed a significant heterogeneity (I2 = 78%).
Nonbleeding Mortality and Bleeding Mortality
In total, 48 studies (eAppendix 16 in the Supplement) assessed nonbleeding mortality in 46 619 patients (n = 23 458 TXA group vs n = 23 161 control group). Death occurred in 1180 patients (5%) in the TXA group and 1228 patients (5%) in the control group. Overall, administration of intravenous TXA was not associated with a decreased risk for nonbleeding mortality (RD = −0.002; 95% CI, −0.006 to 0.002; P = .29) (eTable 7; eFigure 21 in the Supplement). However, subgroup analysis showed a significant increase for nonbleeding mortality in patients with neurological conditions of the TXA group (RD = 0.044; 95% CI, 0.007-0.081; P = .02), whereas the subgroup analysis of cardiothoracic surgery showed a significant decrease for nonbleeding mortality in patients of the TXA group (RD = −0.025; 95% CI, −0.045 to −0.005; P = .02). Sensitivity analysis using a random-effects model showed robust effect estimates for nonbleeding mortality (RD = −0.000; 95% CI, −0.002 to 0.001; P = .92) but not for the subgroup of patients with neurological conditions (RD = 0.021; 95% CI, −0.014 to 0.057; P = .24) and cardiothoracic surgery (RD = −0.015; 95% CI, −0.031 to 0.002; P = .10) (eTable 7; eFigure 22 in the Supplement).
In total, 49 studies (eAppendix 17 in the Supplement) assessed the bleeding mortality in 46 702 patients (n = 23 501 TXA group vs n = 23 201 control group). Death occurred in 692 patients (3%) in the TXA group and 874 patients (4%) in the control group. Quiz Ref IDOverall, administration of intravenous TXA was associated with an overall significant decrease of bleeding mortality (RD = −0.008; 95% CI, −0.011 to −0.005; P < .001) (Table 3; eFigure 23 in the Supplement). Subgroup analysis showed a significantly decreased bleeding mortality in patients with neurological conditions (RD = −0.071; 95% CI, −0.102 to −0.041; P < .001), patients with trauma (RD = −0.008; 95% CI, −0.015 to −0.002; P = .008), and patients of any other disciplines of the TXA group (RD = −0.018; 95% CI, −0.033 to −0.004; P = .02), whereas no significant differences could be detected within the remaining medical disciplines (cardiothoracic, gynecological, orthopedic, and pediatric). Sensitivity analysis using a random-effects model showed robust effect estimates for bleeding mortality (RD = −0.004; 95% CI, −0.008 to −0.001; P = .02) but not for the subgroup of other disciplines (RD = −0.01; 95% CI, −0.028 to −0.009; P = .30) (Table 3; eFigure 24 in the Supplement). Significant heterogeneity was detected for patients with neurological conditions (I2 = 60%).
Patients With Risks for Thromboembolic Events
Overall, administration of intravenous TXA was not associated with an increased risk for total TEs (RD = −0.000; 95% CI, −0.008 to 0.009; P > .99) (eFigure 25 in the Supplement), for VT (RD = 0.003; 95% CI, −0.007 to 0.013; P = .57) (eFigure 26 in the Supplement), for PE (RD = −0.001; 95% CI, −0.009 to 0.007; P = .73) (eFigure 27 in the Supplement), or for VTEs (RD = −0.000; 95% CI, −0.012 to 0.01; P = .89) (eFigure 28 in the Supplement). Administration of intravenous TXA was associated with significant reductions in overall mortality (RD = −0.038; 95% CI, −0.057 to −0.018; P < .001). Detailed analyses are reported in eAppendix 7, eFigure 29 and eFigure 30, and eTable 8 in the Supplement.
A meta-regression of 143 intervention groups was conducted to assess a possible association between different intravenous dosages of TXA and VTE rate. Results from this analysis showed no association between total dosing (RD = −0.005; 95% CI, −0.021 to 0.011; P = .53), single dosing (RD = 0.018; 95% CI, −0.053 to 0.09; P = .60), or any dose of intravenous TXA (RD = −0.005; 95% CI, −0.013 to 0.003; P = .21) and incidence of VTEs. Detailed analyses are reported in eAppendix 8 in the Supplement.
Overall, 139 studies (72%) were judged with low risk and 10 (5%) at high risk for random sequence generation. The risk of bias in the remaining 43 studies (22%) was unclear because of insufficient information. Allocation was adequately concealed in 68 studies (35%), whereas 4 studies (2%) were judged at high risk because patients were not randomly assigned to intravenous TXA or the control group. Sensitivity analysis with studies judged at low risk for selection bias was performed for total TEs and showed that results remained robust (RD = -0.001, 95% CI, −0.002 to 0.003, P = .89) (eFigure 33 in the Supplement). Detailed analysis including funnel plots is reported in eAppendix 9 and in eFigures 31-36 in the Supplement.
A systematic search was performed to identify RCTs published between July 1, 2018, and December 31, 2020. In total, 72 studies were considered for full-text review, of which 48 were excluded because of ineligible study designs or control groups (n = 35), ineligible end points (n = 5), missing or nontranslatable full text (n = 4), and duplicates (n = 4), leaving 24 RCTs206-229 including 27 888 patients (14 242 TXA group and 13 646 control group) for analysis (eTable 9 in the Supplement).
Of all trials (n = 216) comprising 125 550 patients, we found 1020 total TEs (2.1%) in the TXA group and 900 total TEs (2.0%) in the control group. The addition of 24 trials published after our analysis was completed showed that effect estimates for total TEs (RD = 0.001; 95% CI, −0.001 to 0.002; P = .49), VT (RD = −0.000; 95% CI, −0.001 to 0.001; P = .85), PE (RD = 0.000; 95% CI, −0.001 to 0.001; P = .74), VTE (RD = 0.000; 95% CI, −0.001 to 0.002; P = .85), and overall mortality (RD = −0.007; 95% CI, −0.012 to −0.004; P < .001) remained robust (eTables 10-14; eFigures 37-46 in the Supplement). Sensitivity analysis for total TEs using the RR as an effect measure including studies with (RR = 1.02; 95% CI, 0.94-1.11; P = .56) and without (RR = 1.03; 95% CI, 0.95-1.12; P = .52) double-zero events showed similar results.Detailed analyses are reported in eAppendix 10 and eFigures 37-48 in the Supplement.
Tranexamic acid is efficient to reduce bleeding by inhibiting the enzymatic breakdown of existing fibrin blood clots and is therefore widely used in anesthesia and surgery. The utility of TXA was supported by the results of 3 trials (CRASH-2, WOMAN and CRASH-3), reporting its efficiency in reducing bleeding-associated deaths in patients with trauma,41 postpartum hemorrhage,40 and traumatic brain injury.206 However, a significant survival benefit was achieved only when TXA was administered within the first 3 hours after injury or delivery.40,41 On the basis of the CRASH-2 results, intravenous TXA was included in the World Health Organization list of essential medicine in 2011.230 Along with the positive effect, concerns about potential adverse effects, in particular vascular occlusive events, were raised. Controversial results were published, reporting from no incidence of TE40 up to 12-fold higher rates for DVT7 after intravenous TXA administration. Yates and colleagues231 performed a meta-analysis including RCTs with different application methods of TXA. Analysis of 20 679 patients revealed no increased risk for VTEs after administration of intravenous TXA compared with placebo or no intervention. No subgroup analysis was performed by the authors. In orthopedic patients undergoing surgery with or without intravenous TXA, a systematic review by Franchini and colleagues232 encompassing 67 RCTs revealed no significant difference of VTEs measured as RD including studies with 0 events (RD, 0.0008) and RR excluding these studies (RR, 1.0411).
To assess any risk of TEs associated with administration of intravenous TXA, we performed a meta-analysis including studies from all medical disciplines that assessed and provided data for TEs. Analyses were performed using RD including studies with 0 events to allow a general conclusion. Although this method yields wide 95% CIs when events are rare, this approach provides precise information when analyzing all available evidence instead of excluding a large proportion of studies that provided double-zero events. Excluding these trials from analysis generates the risk of inflating the magnitude of the pooled treatment effect. However, we performed a sensitivity analysis using the RR as an effect measure with and without studies with double-zero events and revealed robust effect estimates. In total, 216 studies published between 1976 and 2020 encompassing 125 500 patients were included in the meta-analysis, and overall we found 1020 total TEs (2.1%) in the TXA group and 900 total TEs (2.0%) in the control group. There was no association between intravenous TXA and increased risk for vascular occlusive events. The bleeding-associated mortality was significantly reduced in intravenous TXA–treated patients compared with controls, whereas no difference in nonbleeding mortality was detected. Particularly, the use of intravenous TXA in patients experiencing major trauma and in patients with neurological conditions was associated with significant survival benefit concerning bleeding-related mortality. Notably, we found only 1 study providing data for patients with major trauma treated with intravenous TXA. An updated meta-analysis was performed to identify RCTs published recently. Our results remain unchanged when data from these trials for total TEs, VT, PE, VTE, and overall mortality were included in the meta-analysis.
Of all investigated subgroups, we found inconclusive results for patients with neurological conditions. In this subgroup, results obtained with the fixed-effect model did not remain robust when using the random-effects model for the end points of TE and nonbleeding mortality. However, we found a decrease in bleeding-associated mortality in patients of the TXA group compared with the control group. In total, 12 studies provided data for total TEs in patients with neurological conditions; study size varied between 24 and 2235. Heterogeneity remained high after omitting studies with more than 1000 patients. Overall, increased heterogeneity and asymmetry in funnel plots indicate that further trials are necessary to solve the uncertainty for patients with neurological conditions.
It is commonly held that trials with low numbers of recruited patients might be underpowered to detect an intervention effect. To address this possibility, we performed a sensitivity analysis and found that administration of intravenous TXA was not associated with an increased risk for total TEs in studies with less than or equal to 99 patients, 100 to 999 patients, and greater than or equal to 1000 patients. Patients with an increased risk for thromboembolism were often excluded from RCTs. Given the short elimination half-life of intravenous TXA, patients with a risk factor may benefit from treatment during surgery. We found that the risk for vascular occlusive events or overall mortality rate was not increased in studies including patients with increased risks for thromboembolism. To assess a possible effect of study size or risk of bias, we conducted sensitivity analyses for the primary endpoint of total TEs, with results remaining robust.
Overall, the administration dose of intravenous TXA varied widely from 0.5 to 5 g or 10 to 100 mg/kg. Moving away from one-dose-fits-all to weight-adapted dosing might be associated with the different treatment regimens applied worldwide in the context of trauma and surgery. Notably, we did not detect any dose-dependent association of TEs.
Although this meta-analysis provides substantial data, this study has limitations. We cannot exclude that additional references might have been missed by our systematic search of databases. However, we believe that inclusion of further studies had no impact on our main findings regarding vascular occlusive events. The follow-up varied between trials, ranging from 24 hours to several months. However, the half-life of intravenous TXA is 1.9-2.7 hours.233,234 Considering that postoperative thrombotic events occur 6 to 8 days after surgery,235 we hypothesized that intravenous TXA–related adverse events would be detected within even in a short period of follow-up. Furthermore, TEs were not examined using ultrasonographic screening; therefore, asymptomatic thrombosis might not have been detected in all cases, and the incidence of TEs might be underestimated in some studies. Low incidence of VTEs with an approximate rate of 1 per 1000 patients236 and the routine use of postoperative thrombosis prophylaxis might also be associated with a low detection rate in patients with and without administration of intravenous TXA. Many of the included studies did not provide sufficient information about thrombosis prophylaxis; therefore, the association of postoperative care and vascular occlusive events was not analyzed further.
Taken as a whole, this systematic review and meta-analysis did not find that intravenous treatment with TXA in patients of any medical discipline was associated with a significant increased risk for TEs irrespective of administered dose. The results of this study suggest that use of intravenous TXA may have utility in all medical fields, with some uncertainty for patients with neurological conditions.
Accepted for Publication: January 14, 2021.
Published Online: April 14, 2021. doi:10.1001/jamasurg.2021.0884
Corresponding Author: Patrick Meybohm, MD, Department of Anaesthesiology, Intensive Care, Emergency and Pain Medicine, University Hospital Wuerzburg, Oberduerrbacher Str 6, 97080 Wuerzburg, Germany (meybohm_p@ukw.de).
Author Contributions: Dr Meybohm had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. Drs Choorapoikayil and Meybohm contributed equally to this work. Ms Taeuber and Drs Meybohm and Choorapoikayil are guarantors.
Concept and design: Taeuber, Neef, Kranke, Choorapoikayil, Meybohm.
Acquisition, analysis, or interpretation of data: Taeuber, Weibel, Herrmann, Schlesinger, Kranke, Messroghli, Zacharowski, Choorapoikayil, Meybohm.
Drafting of the manuscript: Taeuber, Kranke, Choorapoikayil, Meybohm.
Critical revision of the manuscript for important intellectual content: All authors.
Statistical analysis: Taeuber, Weibel, Herrmann, Kranke, Choorapoikayil, Meybohm.
Administrative, technical, or material support: Kranke.
Supervision: Kranke, Zacharowski, Choorapoikayil, Meybohm.
Conflict of Interest Disclosures: Dr Kranke reported other support from FreseniusKabi speakers fee, personal fees from TevaRatiopharm, and other support from CSL Behring speakers fee outside the submitted work. Dr Zacharowski reported grants from B. Braun, grants from Fresenius, grants from CSL Behring, and grants from Vifor outside the submitted work. Dr Meybohm reported other support from B Braun Melsungen for the implementation of Frankfurt's Patient Blood Management program, other support from CSL Behring for the implementation of Frankfurt's Patient Blood Management program, other support from Fresenius Kabi for the implementation of Frankfurt's Patient Blood Management program, and other support from Vifor Pharma for the implementation of Frankfurt's Patient Blood Management program during the conduct of the study; other support from B Braun Melsungen honoraria for scientific lectures, other support from CSL Behring honoraria for scientific lectures, other support from Fresenius Kabi honoraria for scientific lectures, and other support from Vifor Pharma honoraria for scientific lectures outside the submitted work. No other disclosures were reported.
Additional Contributions: We thank Elisabeth Adam, MD, and Florian Piekarski, MD, from University Hospital Frankfurt for critical discussion. No compensation was received.
1.Spence
J, LeManach
Y, Chan
MTV,
et al; Vascular Events in Noncardiac Surgery Patients Cohort Evaluation (VISION) Study Investigators. Association between complications and death within 30 days after noncardiac surgery.
CMAJ. 2019;191(30):E830-E837. doi:
10.1503/cmaj.190221PubMedGoogle ScholarCrossref 2.Poeran
J, Rasul
R, Suzuki
S,
et al. Tranexamic acid use and postoperative outcomes in patients undergoing total hip or knee arthroplasty in the United States: retrospective analysis of effectiveness and safety.
BMJ. 2014;349:g4829. doi:
10.1136/bmj.g4829
PubMedGoogle ScholarCrossref 3.Ker
K, Edwards
P, Perel
P, Shakur
H, Roberts
I. Effect of tranexamic acid on surgical bleeding: systematic review and cumulative meta-analysis.
BMJ. 2012;344:e3054. doi:
10.1136/bmj.e3054
PubMedGoogle Scholar 6.Sprigg
N, Flaherty
K, Appleton
JP,
et al; TICH-2 Investigators. Tranexamic acid for hyperacute primary IntraCerebral Haemorrhage (TICH-2): an international randomised, placebo-controlled, phase 3 superiority trial.
Lancet. 2018;391(10135):2107-2115. doi:
10.1016/S0140-6736(18)31033-X
PubMedGoogle ScholarCrossref 11.American Society of Anesthesiologists Task Force on Perioperative Blood Management. Practice guidelines for perioperative blood management: an updated report by the American Society of Anesthesiologists Task Force on Perioperative Blood Management.
Anesthesiology. 2015;122(2):241-275. doi:
10.1097/ALN.0000000000000463
PubMedGoogle ScholarCrossref 12.Rossaint
R, Bouillon
B, Cerny
V,
et al. The European guideline on management of major bleeding and coagulopathy following trauma: fourth edition.
Crit Care. 2016 12;20:100. doi:
10.1186/s13054-016-1265-xGoogle Scholar 13.Spahn
DR, Bouillon
B, Cerny
V,
et al. The European guideline on management of major bleeding and coagulopathy following trauma: fifth edition.
Crit Care. Published online March 27, 2019. doi:
10.1186/s13054-019-2347-3Google Scholar 15.Celebi
N, Celebioglu
B, Selcuk
M, Canbay
O, Karagoz
AH, Aypar
U. The role of antifibrinolytic agents in gynecologic cancer surgery.
Saudi Med J. 2006;27(5):637-641.
PubMedGoogle Scholar 19.Rashmi
PS, Sudha
TR, Prema
P, Rajashri
P, Vijayanath
V. Role of tranexamic acid in reducing blood loss during and after cesarean section: a randomized case control prospective study.
J Med Res Pract. 2012;1(2):40-43.
Google Scholar 21.Gungorduk
K, Yıldırım
G, Asıcıoğlu
O, Gungorduk
OC, Sudolmus
S, Ark
C. Efficacy of intravenous tranexamic acid in reducing blood loss after elective cesarean section: a prospective, randomized, double-blind, placebo-controlled study.
Am J Perinatol. 2011;28(3):233-240. doi:
10.1055/s-0030-1268238
PubMedGoogle ScholarCrossref 24.Abdel-Aleem
H, Alhusaini
TK, Abdel-Aleem
MA, Menoufy
M, Gülmezoglu
AM. Effectiveness of tranexamic acid on blood loss in patients undergoing elective cesarean section: randomized clinical trial.
J Matern Fetal Neonatal Med. 2013;26(17):1705-1709. doi:
10.3109/14767058.2013.794210
PubMedGoogle ScholarCrossref 25.Goswami
U, Sarangi
S, Gupta
S, Babbar
S. Comparative evaluation of two doses of tranexamic acid used prophylactically in anemic parturients for lower segment cesarean section: a double-blind randomized case control prospective trial.
Saudi J Anaesth. 2013;7(4):427-431. doi:
10.4103/1658-354X.121077
PubMedGoogle ScholarCrossref 26.Gungorduk
K, Asıcıoğlu
O, Yıldırım
G, Ark
C, Tekirdağ
AI, Besımoglu
B. Can intravenous injection of tranexamic acid be used in routine practice with active management of the third stage of labor in vaginal delivery? a randomized controlled study.
Am J Perinatol. 2013;30(5):407-413. doi:
10.1097/01.ogx.0000436756.05118.cd
PubMedGoogle Scholar 28.Shahid
A, Khan
A. Tranexamic acid in decreasing blood loss during and after caesarean section.
J Coll Physicians Surg Pak. 2013;23(7):459-462.
PubMedGoogle Scholar 31.Lundin
ES, Johansson
T, Zachrisson
H,
et al. Single-dose tranexamic acid in advanced ovarian cancer surgery reduces blood loss and transfusions: double-blind placebo-controlled randomized multicenter study.
Acta Obstet Gynecol Scand. 2014;93(4):335-344. doi:
10.1111/aogs.12333
PubMedGoogle ScholarCrossref 38.Shaaban
MM, Ahmed
MR, Farhan
RE, Dardeer
HH. Efficacy of tranexamic acid on myomectomy-associated blood loss in patients with multiple myomas: a randomized controlled clinical trial.
Reprod Sci. 2016;23(7):908-912. doi:
10.1177/1933719115623646
PubMedGoogle ScholarCrossref 40.WOMAN Trial Collaborators. Effect of early tranexamic acid administration on mortality, hysterectomy, and other morbidities in women with post-partum haemorrhage (WOMAN): an international, randomised, double-blind, placebo-controlled trial.
Lancet. 2017;389(10084):2105-2116. doi:
10.1016/S0140-6736(17)30638-4
PubMedGoogle ScholarCrossref 41.Shakur
H, Roberts
I, Bautista
R,
et al; CRASH-2 Trial Collaborators. Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Lancet. 2010;376(9734):23-32. doi:
10.1016/S0140-6736(10)60835-5PubMedGoogle ScholarCrossref 44.Sankar
D, Krishnan
R, Veerabahu
M, Vikraman
B. Evaluation of the efficacy of tranexamic acid on blood loss in orthognathic surgery: a prospective, randomized clinical study.
Int J Oral Maxillofac Surg. 2012;41(6):713-717. doi:
10.1016/j.ijom.2012.01.008
PubMedGoogle ScholarCrossref 46.Nuhi
S, Goljanian Tabrizi
A, Zarkhah
L, Rashedi Ashrafi
B. Impact of intravenous tranexamic acid on hemorrhage during endoscopic sinus surgery.
Iran J Otorhinolaryngol. 2015;27(82):349-354.
PubMedGoogle Scholar 47.Apipan
B, Rummasak
D, Narainthonsaenee
T. The effect of different dosage regimens of tranexamic acid on blood loss in bimaxillary osteotomy: a randomized, double-blind, placebo-controlled study.
Int J Oral Maxillofac Surg. 2018;47(5):608-612. doi:
10.1016/j.ijom.2017.10.007
PubMedGoogle ScholarCrossref 49.Benoni
G, Fredin
H. Fibrinolytic inhibition with tranexamic acid reduces blood loss and blood transfusion after knee arthroplasty: a prospective, randomised, double-blind study of 86 patients.
J Bone Joint Surg Br. 1996;78(3):434-440. doi:
10.1302/0301-620X.78B3.0780434
PubMedGoogle ScholarCrossref 51.Jansen
AJ, Andreica
S, Claeys
M, D’Haese
J, Camu
F, Jochmans
K. Use of tranexamic acid for an effective blood conservation strategy after total knee arthroplasty.
Br J Anaesth. 1999;83(4):596-601. doi:
10.1093/bja/83.4.596
PubMedGoogle ScholarCrossref 60.Husted
H, Blønd
L, Sonne-Holm
S, Holm
G, Jacobsen
TW, Gebuhr
P. Tranexamic acid reduces blood loss and blood transfusions in primary total hip arthroplasty: a prospective randomized double-blind study in 40 patients.
Acta Orthop Scand. 2003;74(6):665-669. doi:
10.1080/00016470310018171
PubMedGoogle ScholarCrossref 62.Lemay
E, Guay
J, Côté
C, Roy
A. Tranexamic acid reduces the need for allogenic red blood cell transfusions in patients undergoing total hip replacement.
Can J Anaesth. 2004;51(1):31-37. doi:
10.1007/BF03018543
PubMedGoogle ScholarCrossref 67.Camarasa
MA, Ollé
G, Serra-Prat
M,
et al. Efficacy of aminocaproic, tranexamic acids in the control of bleeding during total knee replacement: a randomized clinical trial.
Br J Anaesth. 2006;96(5):576-582. doi:
10.1093/bja/ael057
PubMedGoogle ScholarCrossref 70.Molloy
DO, Archbold
HA, Ogonda
L, McConway
J, Wilson
RK, Beverland
DE. Comparison of topical fibrin spray and tranexamic acid on blood loss after total knee replacement: a prospective, randomised controlled trial.
J Bone Joint Surg Br. 2007;89(3):306-309. doi:
10.1302/0301-620X.89B3.17565
PubMedGoogle ScholarCrossref 73.Elwatidy
S, Jamjoom
Z, Elgamal
E, Zakaria
A, Turkistani
A, El-Dawlatly
A. Efficacy and safety of prophylactic large dose of tranexamic acid in spine surgery: a prospective, randomized, double-blind, placebo-controlled study.
Spine (Phila Pa 1976). 2008;33(24):2577-2580. doi:
10.1097/BRS.0b013e318188b9c5
PubMedGoogle ScholarCrossref 75.Kakar
PN, Gupta
N, Govil
P, Shah
V. Efficacy and safety of tranexamic acid in control of bleeding following TKR: a randomized clinical trial.
Indian J Anaesth. 2009;53(6):667-671.
PubMedGoogle Scholar 78.Zufferey
PJ, Miquet
M, Quenet
S,
et al; Tranexamic Acid in Hip-Fracture Surgery (THIF) Study. Tranexamic acid in hip fracture surgery: a randomized controlled trial.
Br J Anaesth. 2010;104(1):23-30. doi:
10.1093/bja/aep314PubMedGoogle ScholarCrossref 86.Chareancholvanich
K, Siriwattanasakul
P, Narkbunnam
R, Pornrattanamaneewong
C. Temporary clamping of drain combined with tranexamic acid reduce blood loss after total knee arthroplasty: a prospective randomized controlled trial.
BMC Musculoskelet Disord. 2012;13:124. doi:
10.1186/1471-2474-13-124
PubMedGoogle ScholarCrossref 88.Lin
PC, Hsu
CH, Huang
CC, Chen
WS, Wang
JW. The blood-saving effect of tranexamic acid in minimally invasive total knee replacement: is an additional pre-operative injection effective?
J Bone Joint Surg Br. 2012;94(7):932-936. doi:
10.1302/0301-620X.94B7.28386
PubMedGoogle ScholarCrossref 89.Raviraj
A, Anand
A, Chakravarthy
M, Kumarswamy
S, Prabhu
A, Pai
S. Tranexamic acid reduces blood loss in simultaneous bilateral total knee arthroplasty: a randomized control trial.
Eur J Orthop Surg Traumatol. 2012;22(5):381-386. doi:
10.1007/s00590-011-0845-3Google ScholarCrossref 91.Aguilera
X, Martinez-Zapata
MJ, Bosch
A,
et al. Efficacy and safety of fibrin glue and tranexamic acid to prevent postoperative blood loss in total knee arthroplasty: a randomized controlled clinical trial.
J Bone Joint Surg Am. 2013;95(22):2001-2007. doi:
10.2106/JBJS.L.01182
PubMedGoogle ScholarCrossref 93.Lee
SH, Cho
KY, Khurana
S, Kim
KI. Less blood loss under concomitant administration of tranexamic acid and indirect factor Xa inhibitor following total knee arthroplasty: a prospective randomized controlled trial.
Knee Surg Sports Traumatol Arthrosc. 2013;21(11):2611-2617. doi:
10.1007/s00167-012-2213-1
PubMedGoogle ScholarCrossref 95.Seo
JG, Moon
YW, Park
SH, Kim
SM, Ko
KR. The comparative efficacies of intra-articular and intravenous tranexamic acid for reducing blood loss during total knee arthroplasty.
Knee Surg Sports Traumatol Arthrosc. 2013;21(8):1869-1874. doi:
10.1007/s00167-012-2079-2
PubMedGoogle ScholarCrossref 97.Wang
Q, Liu
J, Fan
R,
et al. Tranexamic acid reduces postoperative blood loss of degenerative lumbar instability with stenosis in posterior approach lumbar surgery: a randomized controlled trial.
Eur Spine J. 2013;22(9):2035-2038. doi:
10.1007/s00586-013-2836-z
PubMedGoogle ScholarCrossref 98.Bidolegui
F, Arce
G, Lugones
A, Pereira
S, Vindver
G. Tranexamic acid reduces blood loss and transfusion in patients undergoing total knee arthroplasty without tourniquet: a prospective randomized controlled trial.
Open Orthop J. 2014;8:250-254. doi:
10.2174/1874325001408010250
PubMedGoogle ScholarCrossref 99.Emara
WM, Moez
KK, Elkhouly
AH. Topical versus intravenous tranexamic acid as a blood conservation intervention for reduction of post-operative bleeding in hemiarthroplasty.
Anesth Essays Res. 2014;8(1):48-53. doi:
10.4103/0259-1162.128908
PubMedGoogle ScholarCrossref 100.Kim
TK, Chang
CB, Kang
YG,
et al. Clinical value of tranexamic acid in unilateral and simultaneous bilateral TKAs under a contemporary blood-saving protocol: a randomized controlled trial.
Knee Surg Sports Traumatol Arthrosc. 2014;22(8):1870-1878. doi:
10.1007/s00167-013-2492-1
PubMedGoogle ScholarCrossref 101.Oremus
K, Sostaric
S, Trkulja
V, Haspl
M. Influence of tranexamic acid on postoperative autologous blood retransfusion in primary total hip and knee arthroplasty: a randomized controlled trial.
Transfusion. 2014;54(1):31-41. doi:
10.1111/trf.12224
PubMedGoogle ScholarCrossref 102.Sarzaeem
MM, Razi
M, Kazemian
G, Moghaddam
ME, Rasi
AM, Karimi
M. Comparing efficacy of three methods of tranexamic acid administration in reducing hemoglobin drop following total knee arthroplasty.
J Arthroplasty. 2014;29(8):1521-1524. doi:
10.1016/j.arth.2014.02.031
PubMedGoogle ScholarCrossref 103.Verma
K, Errico
T, Diefenbach
C,
et al. The relative efficacy of antifibrinolytics in adolescent idiopathic scoliosis: a prospective randomized trial.
J Bone Joint Surg Am. 2014;96(10):e80. doi:
10.2106/JBJS.L.00008
PubMedGoogle Scholar 105.Digas
G, Koutsogiannis
I, Meletiadis
G, Antonopoulou
E, Karamoulas
V, Bikos
CH. Intra-articular injection of tranexamic acid reduce blood loss in cemented total knee arthroplasty.
Eur J Orthop Surg Traumatol. 2015;25(7):1181-1188. doi:
10.1007/s00590-015-1664-8
PubMedGoogle ScholarCrossref 106.Hsu
CH, Lin
PC, Kuo
FC, Wang
JW. A regime of two intravenous injections of tranexamic acid reduces blood loss in minimally invasive total hip arthroplasty: a prospective randomised double-blind study.
Bone Joint J. 2015;97-B(7):905-910. doi:
10.1302/0301-620X.97B7.35029
PubMedGoogle ScholarCrossref 107.Jaszczyk
M, Kozerawski
D, Kołodziej
Ł, Kazimierczak
A, Sarnecki
P, Sieczka
Ł. Effect of single preoperative dose of tranexamic acid on blood loss and transfusion in hip arthroplasty.
Ortop Traumatol Rehabil. 2015;17(3):265-273. doi:
10.5604/15093492.1162426
PubMedGoogle ScholarCrossref 108.Karaaslan
F, Karaoğlu
S, Yurdakul
E. Reducing intra-articular hemarthrosis after arthroscopic anterior cruciate ligament reconstruction by the administration of intravenous tranexamic acid: a prospective, randomized controlled trial.
Am J Sports Med. 2015;43(11):2720-2726. doi:
10.1177/0363546515599629
PubMedGoogle ScholarCrossref 109.Kundu
R, Das
A, Basunia
SR, Bhattacharyya
T, Chattopadhyay
S, Mukherjee
A. Does a single loading dose of tranexamic acid reduce perioperative blood loss and transfusion requirements after total knee replacement surgery? a randomized, controlled trial.
J Nat Sci Biol Med. 2015;6(1):94-99. doi:
10.4103/0976-9668.149099
PubMedGoogle ScholarCrossref 110.Lin
SY, Chen
CH, Fu
YC, Huang
PJ, Chang
JK, Huang
HT. The efficacy of combined use of intraarticular and intravenous tranexamic acid on reducing blood loss and transfusion rate in total knee arthroplasty.
J Arthroplasty. 2015;30(5):776-780. doi:
10.1016/j.arth.2014.12.001
PubMedGoogle ScholarCrossref 111.Motififard
M, Tahririan
MA, Saneie
M, Badiei
S, Nemati
A. Low dose perioperative intravenous tranexamic acid in patients undergoing total knee arthroplasty: a double-blind randomized placebo controlled clinical trial.
J Blood Transfus. 2015;2015:948304. doi:
10.1155/2015/948304
PubMedGoogle Scholar 112.Öztaş
S, Öztürk
A, Akalin
Y,
et al. The effect of local and systemic application of tranexamic acid on the amount of blood loss and allogeneic blood transfusion after total knee replacement.
Acta Orthop Belg. 2015;81(4):698-707.
PubMedGoogle Scholar 116.Shinde
A, Sobti
A, Maniar
S, Mishra
A, Gite
R, Shetty
V. Tranexamic acid reduces blood loss and need of blood transfusion in total knee arthroplasty: a prospective, randomized, double-blind study in Indian population.
Asian J Transfus Sci. 2015;9(2):168-172. doi:
10.4103/0973-6247.154251
PubMedGoogle ScholarCrossref 120.Chen
X, Cao
X, Yang
C, Guo
K, Zhu
Q, Zhu
J. Effectiveness and safety of fixed-dose tranexamic acid in simultaneous bilateral total knee arthroplasty: a randomized double-blind controlled trial.
J Arthroplasty. 2016;31(11):2471-2475. doi:
10.1016/j.arth.2016.04.003
PubMedGoogle ScholarCrossref 121.Drosos
GI, Ververidis
A, Valkanis
C,
et al. A randomized comparative study of topical versus intravenous tranexamic acid administration in enhanced recovery after surgery (ERAS) total knee replacement.
J Orthop. 2016;13(3):127-131. doi:
10.1016/j.jor.2016.03.007
PubMedGoogle ScholarCrossref 122.Keyhani
S, Esmailiejah
AA, Abbasian
MR, Safdari
F. Which route of tranexamic acid administration is more effective to reduce blood loss following total knee arthroplasty?
Arch Bone Jt Surg. 2016;4(1):65-69.
PubMedGoogle Scholar 123.Seviciu
A, Gross
I, Fathima
S, Walsh
SM. Effects of tranexamic acid and bipolar sealer alone or in combination in primary total knee arthroplasty: a prospective, randomized, controlled trial.
Arthroplast Today. 2016;2(2):77-82. doi:
10.1016/j.artd.2015.12.007
PubMedGoogle ScholarCrossref 124.Tzatzairis
TK, Drosos
GI, Kotsios
SE, Ververidis
AN, Vogiatzaki
TD, Kazakos
KI. Intravenous vs topical tranexamic acid in total knee arthroplasty without tourniquet application: a randomized controlled study.
J Arthroplasty. 2016;31(11):2465-2470. doi:
10.1016/j.arth.2016.04.036
PubMedGoogle ScholarCrossref 127.Yi
Z, Bin
S, Jing
Y, Zongke
Z, Pengde
K, Fuxing
P. Tranexamic acid administration in primary total hip arthroplasty: a randomized controlled trial of intravenous combined with topical versus single-dose intravenous administration.
J Bone Joint Surg Am. 2016;98(12):983-991. doi:
10.2106/JBJS.15.00638
PubMedGoogle ScholarCrossref 128.Zekcer
A, Del Priori
R, Tieppo
C, da Silva
RS, Severino
NR. Topical vs intravenous administration of tranexamic acid in knee arthroplasty and prevalence of deep venous thrombosis: a randomized clinical trial.
J Vasc Bras. 2016;15(2):120-125. doi:
10.1590/1677-5449.007515
PubMedGoogle ScholarCrossref 131.Huang
Z, Xie
X, Li
L,
et al. Intravenous and topical tranexamic acid alone are superior to tourniquet use for primary total knee arthroplasty: a prospective, randomized controlled trial.
J Bone Joint Surg Am. 2017;99(24):2053-2061. doi:
10.2106/JBJS.16.01525
PubMedGoogle ScholarCrossref 132.Lacko
M, Cellar
R, Schreierova
D, Vasko
G. Comparison of intravenous and intra-articular tranexamic acid in reducing blood loss in primary total knee replacement.
Eklem Hastalik Cerrahisi. 2017;28(2):64-71. doi:
10.5606/ehc.2017.54914
PubMedGoogle ScholarCrossref 133.Melo
GLR, Lages
DS, Madureira Junior
JL, Pellucci
GP, Pellucci
JWJ. The use of tranexamic acid in patients submitted to primary total hip arthroplasty: an evaluation of its impact in different administration protocols.
Rev Bras Ortop. 2017;52(suppl 1):34-39. doi:
10.1016/j.rbo.2017.06.007
PubMedGoogle ScholarCrossref 134.Prakash
J, Seon
JK, Park
YJ, Jin
C, Song
EK. A randomized control trial to evaluate the effectiveness of intravenous, intra-articular and topical wash regimes of tranexamic acid in primary total knee arthroplasty.
J Orthop Surg (Hong Kong). 2017;25(1):2309499017693529. doi:
10.1177/2309499017693529
PubMedGoogle Scholar 135.Song
EK, Seon
JK, Prakash
J, Seol
YJ, Park
YJ, Jin
C. Combined administration of intravenous and topical tranexamic acid is not superior to either individually in primary navigated TKA.
J Arthroplasty. 2017;32(1):37-42. doi:
10.1016/j.arth.2016.06.052
PubMedGoogle ScholarCrossref 138.Uğurlu
M, Aksekili
MA, Çağlar
C, Yüksel
K, Şahin
E, Akyol
M. Effect of topical and intravenously applied tranexamic acid compared to control group on bleeding in primary unilateral total knee arthroplasty.
J Knee Surg. 2017;30(2):152-157. doi:
10.1055/s-0036-1583270
PubMedGoogle ScholarCrossref 139.Vara
AD, Koueiter
DM, Pinkas
DE, Gowda
A, Wiater
BP, Wiater
JM. Intravenous tranexamic acid reduces total blood loss in reverse total shoulder arthroplasty: a prospective, double-blinded, randomized, controlled trial.
J Shoulder Elbow Surg. 2017;26(8):1383-1389. doi:
10.1016/j.jse.2017.01.005
PubMedGoogle ScholarCrossref 140.Wang
J, Wang
Q, Zhang
X, Wang
Q. Intra-articular application is more effective than intravenous application of tranexamic acid in total knee arthroplasty: a prospective randomized controlled trial.
J Arthroplasty. 2017;32(11):3385-3389. doi:
10.1016/j.arth.2017.06.024
PubMedGoogle ScholarCrossref 141.Wang
JW, Chen
B, Lin
PC, Yen
SH, Huang
CC, Kuo
FC. The efficacy of combined use of rivaroxaban and tranexamic acid on blood conservation in minimally invasive total knee arthroplasty: a double-blind randomized, controlled trial.
J Arthroplasty. 2017;32(3):801-806. doi:
10.1016/j.arth.2016.08.020
PubMedGoogle ScholarCrossref 142.Watts
CD, Houdek
MT, Sems
SA, Cross
WW, Pagnano
MW. Tranexamic acid safely reduced blood loss in hemi- and total hip arthroplasty for acute femoral neck fracture: a randomized clinical trial.
J Orthop Trauma. 2017;31(7):345-351. doi:
10.1097/BOT.0000000000000837
PubMedGoogle ScholarCrossref 143.Yen
SH, Lin
PC, Chen
B, Huang
CC, Wang
JW. Topical tranexamic acid reduces blood loss in minimally invasive total knee arthroplasty receiving rivaroxaban.
Biomed Res Int. 2017;2017:9105645. doi:
10.1155/2017/9105645
PubMedGoogle Scholar 144.Yuan
X, Li
B, Wang
Q, Zhang
X. Comparison of 3 routes of administration of tranexamic acid on primary unilateral total knee arthroplasty: a prospective, randomized, controlled study.
J Arthroplasty. 2017;32(9):2738-2743. doi:
10.1016/j.arth.2017.03.059
PubMedGoogle ScholarCrossref 146.Zeng
Y, Si
HB, Shen
B,
et al. Intravenous combined with topical administration of tranexamic acid in primary total hip arthroplasty: a randomized controlled trial.
Orthop Surg. 2017;9(2):174-179. doi:
10.1111/os.12287
PubMedGoogle ScholarCrossref 147.Liu
W, Yang
C, Huang
X, Liu
R. Tranexamic acid reduces occult blood loss, blood transfusion, and improves recovery of knee function after total knee arthroplasty: a comparative study.
J Knee Surg. 2018;31(3):239-246. doi:
10.1055/s-0037-1602248
PubMedGoogle ScholarCrossref 150.Zhao
H, Xiang
M, Xia
Y, Shi
X, Pei
FX, Kang
P. Efficacy of oral tranexamic acid on blood loss in primary total hip arthroplasty using a direct anterior approach: a prospective randomized controlled trial.
Int Orthop. 2018;42(11):2535-2542. doi:
10.1007/s00264-018-3846-6
PubMedGoogle ScholarCrossref 151.Coffey
A, Pittmam
J, Halbrook
H, Fehrenbacher
J, Beckman
D, Hormuth
D. The use of tranexamic acid to reduce postoperative bleeding following cardiac surgery: a double-blind randomized trial.
Am Surg. 1995;61(7):566-568.
PubMedGoogle Scholar 157.Brown
RS, Thwaites
BK, Mongan
PD. Tranexamic acid is effective in decreasing postoperative bleeding and transfusions in primary coronary artery bypass operations: a double-blind, randomized, placebo-controlled trial.
Anesth Analg. 1997;85(5):963-970. doi:
10.1213/00000539-199711000-00003
PubMedGoogle ScholarCrossref 165.Diprose
P, Herbertson
MJ, O’Shaughnessy
D, Deakin
CD, Gill
RS. Reducing allogeneic transfusion in cardiac surgery: a randomized double-blind placebo-controlled trial of antifibrinolytic therapies used in addition to intra-operative cell salvage.
Br J Anaesth. 2005;94(3):271-278. doi:
10.1093/bja/aei044
PubMedGoogle ScholarCrossref 166.Karski
J, Djaiani
G, Carroll
J,
et al. Tranexamic acid and early saphenous vein graft patency in conventional coronary artery bypass graft surgery: a prospective randomized controlled clinical trial.
J Thorac Cardiovasc Surg. 2005;130(2):309-314. doi:
10.1016/j.jtcvs.2004.11.015
PubMedGoogle ScholarCrossref 168.Murphy
GJ, Mango
E, Lucchetti
V,
et al. A randomized trial of tranexamic acid in combination with cell salvage plus a meta-analysis of randomized trials evaluating tranexamic acid in off-pump coronary artery bypass grafting.
J Thorac Cardiovasc Surg. 2006;132(3):475-480, 480.e1-480.e8. doi:
10.1016/j.jtcvs.2006.01.064PubMedGoogle ScholarCrossref 169.Santos
AT, Kalil
RA, Bauemann
C, Pereira
JB, Nesralla
IA. A randomized, double-blind, and placebo-controlled study with tranexamic acid of bleeding and fibrinolytic activity after primary coronary artery bypass grafting.
Braz J Med Biol Res. 2006;39(1):63-69. doi:
10.1590/S0100-879X2006000100007
PubMedGoogle ScholarCrossref 170.Jimenez
JJ, Iribarren
JL, Lorente
L,
et al. Tranexamic acid attenuates inflammatory response in cardiopulmonary bypass surgery through blockade of fibrinolysis: a case control study followed by a randomized double-blind controlled trial.
Crit Care. 2007;11(6):R117. doi:
10.1186/cc6173
PubMedGoogle ScholarCrossref 171.Chakravarthy
M, Muniraj
G, Patil
S, Suryaprakash
S, Mitra
S, Shivalingappa
B. A randomized prospective analysis of alteration of hemostatic function in patients receiving tranexamic acid and hydroxyethyl starch (130/0.4) undergoing off pump coronary artery bypass surgery.
Ann Card Anaesth. 2012;15(2):105-110. doi:
10.4103/0971-9784.95072
PubMedGoogle ScholarCrossref 174.Fodstad
H, Liliequist
B, Schannong
M, Thulin
CA. Tranexamic acid in the preoperative management of ruptured intracranial aneurysms.
Surg Neurol. 1978;10(1):9-15.
PubMedGoogle Scholar 179.Tsementzis
SA, Hitchcock
ER, Meyer
CH. Benefits and risks of antifibrinolytic therapy in the management of ruptured intracranial aneurysms: a double-blind placebo-controlled study.
Acta Neurochir (Wien). 1990;102(1-2):1-10. doi:
10.1007/BF01402177
PubMedGoogle ScholarCrossref 181.Hillman
J, Fridriksson
S, Nilsson
O, Yu
Z, Saveland
H, Jakobsson
KE. Immediate administration of tranexamic acid and reduced incidence of early rebleeding after aneurysmal subarachnoid hemorrhage: a prospective randomized study.
J Neurosurg. 2002;97(4):771-778. doi:
10.3171/jns.2002.97.4.0771
PubMedGoogle ScholarCrossref 182.Yutthakasemsunt
S, Kittiwatanagul
W, Piyavechvirat
P, Thinkamrop
B, Phuenpathom
N, Lumbiganon
P. Tranexamic acid for patients with traumatic brain injury: a randomized, double-blinded, placebo-controlled trial.
BMC Emerg Med. 2013;13:20. doi:
10.1186/1471-227X-13-20
PubMedGoogle ScholarCrossref 184.Arumugam
A, A Rahman
NA, Theophilus
SC, Shariffudin
A, Abdullah
JM. Tranexamic acid as antifibrinolytic agent in non traumatic intracerebral hemorrhages.
Malays J Med Sci. 2015;22(Spec Issue):62-71.
PubMedGoogle Scholar 186.Hooda
B, Chouhan
RS, Rath
GP, Bithal
PK, Suri
A, Lamsal
R. Effect of tranexamic acid on intraoperative blood loss and transfusion requirements in patients undergoing excision of intracranial meningioma.
J Clin Neurosci. 2017;41:132-138. doi:
10.1016/j.jocn.2017.02.053
PubMedGoogle ScholarCrossref 195.Yassen
K, Bellamy
MC, Sadek
SA, Webster
NR. Tranexamic acid reduces blood loss during orthotopic liver transplantation.
Clin Transplant. 1993;7(5):453-458.
Google Scholar 197.Kaspar
M, Ramsay
MA, Nguyen
AT, Cogswell
M, Hurst
G, Ramsay
KJ. Continuous small-dose tranexamic acid reduces fibrinolysis but not transfusion requirements during orthotopic liver transplantation.
Anesth Analg. 1997;85(2):281-285. doi:
10.1097/00000539-199708000-00007PubMedGoogle Scholar 201.Crescenti
A, Borghi
G, Bignami
E,
et al. Intraoperative use of tranexamic acid to reduce transfusion rate in patients undergoing radical retropubic prostatectomy: double blind, randomised, placebo controlled trial.
BMJ. 2011;343:d5701. doi:
10.1136/bmj.d5701
PubMedGoogle ScholarCrossref 203.Jendoubi
A, Malouch
A, Bouzouita
A,
et al. Safety and efficacy of intravenous tranexamic acid in endoscopic transurethral resections in urology: prospective randomized trial. Article in French.
Prog Urol. 2017;27(16):1036-1042. doi:
10.1016/j.purol.2017.09.008
PubMedGoogle ScholarCrossref 205.Tavakoli
N, Mokhtare
M, Agah
S,
et al. Comparison of the efficacy of intravenous tranexamic acid with and without topical administration versus placebo in urgent endoscopy rate for acute gastrointestinal bleeding: a double-blind randomized controlled trial.
United European Gastroenterol J. 2018;6(1):46-54. doi:
10.1177/2050640617714940
PubMedGoogle ScholarCrossref 206.CRASH-3 Trial Collaborators. Effects of tranexamic acid on death, disability, vascular occlusive events and other morbidities in patients with acute traumatic brain injury (CRASH-3): a randomised, placebo-controlled trial.
Lancet. 2019;394(10210):1713-1723. doi:
10.1016/S0140-6736(19)32233-0
PubMedGoogle ScholarCrossref 207.HALT-IT Trial Collaborators. Effects of a high-dose 24-h infusion of tranexamic acid on death and thromboembolic events in patients with acute gastrointestinal bleeding (HALT-IT): an international randomised, double-blind, placebo-controlled trial.
Lancet. 2020;395(10241):1927-1936. doi:
10.1016/S0140-6736(20)30848-5
PubMedGoogle ScholarCrossref 208.Abdul
IF, Amadu
MB, Adesina
KT, Olarinoye
AO, Omokanye
LO. Adjunctive use of tranexamic acid to tourniquet in reducing haemorrhage during abdominal myomectomy: a randomized controlled trial.
Eur J Obstet Gynecol Reprod Biol. 2019;242:150-158. doi:
10.1016/j.ejogrb.2019.09.010
PubMedGoogle ScholarCrossref 209.Batıbay
SG, Türkmen
İ, Duman
S, Çamur
S, Sağlam
N, Batıbay
S. Is tranexamic acid safe and reliable during tibial intramedullary nailing?
Ulus Travma Acil Cerrahi Derg. 2018;24(6):575-580. doi:
10.5505/tjtes.2018.42147PubMedGoogle Scholar 210.Chen
F, Jiang
Z, Li
M, Zhu
X. Efficacy and safety of perioperative tranexamic acid in elderly patients undergoing trochanteric fracture surgery: a randomised controlled trial.
Hong Kong Med J. 2019;25(2):120-126. doi:
10.12809/hkmj187570PubMedGoogle Scholar 211.Clavé
A, Gérard
R, Lacroix
J,
et al. A randomized, double-blind, placebo-controlled trial on the efficacy of tranexamic acid combined with rivaroxaban thromboprophylaxis in reducing blood loss after primary cementless total hip arthroplasty.
Bone Joint J. 2019;101-B(2):207-212. doi:
10.1302/0301-620X.101B2.BJJ-2018-0898.R1PubMedGoogle ScholarCrossref 213.Felli
L, Revello
S, Burastero
G,
et al. Single intravenous administration of tranexamic acid in anterior cruciate ligament reconstruction to reduce postoperative hemarthrosis and increase functional outcomes in the early phase of postoperative rehabilitation: a randomized controlled trial.
Arthroscopy. 2019;35(1):149-157. doi:
10.1016/j.arthro.2018.07.050PubMedGoogle ScholarCrossref 214.Fenger-Eriksen
C, D’Amore Lindholm
A, Nørholt
SE,
et al. Reduced perioperative blood loss in children undergoing craniosynostosis surgery using prolonged tranexamic acid infusion: a randomised trial.
Br J Anaesth. 2019;122(6):760-766. doi:
10.1016/j.bja.2019.02.017
PubMedGoogle ScholarCrossref 215.Karampinas
PK, Megaloikonomos
PD, Lampropoulou-Adamidou
K,
et al. Similar thromboprophylaxis with rivaroxaban and low molecular weight heparin but fewer hemorrhagic complications with combined intra-articular and intravenous tranexamic acid in total knee arthroplasty.
Eur J Orthop Surg Traumatol. 2019;29(2):455-460. doi:
10.1007/s00590-018-2307-7
PubMedGoogle ScholarCrossref 216.Lei
Y, Xie
J, Huang
Q, Huang
W, Pei
F. Additional benefits of multiple-dose tranexamic acid to anti-fibrinolysis and anti-inflammation in total knee arthroplasty: a randomized controlled trial.
Arch Orthop Trauma Surg. 2020;140(8):1087-1095. doi:
10.1007/s00402-020-03442-2
PubMedGoogle ScholarCrossref 218.Liu
YF, Hong
CK, Hsu
KL,
et al. Intravenous administration of tranexamic acid significantly improved clarity of the visual field in arthroscopic shoulder surgery: a prospective, double-blind, and randomized controlled trial.
Arthroscopy. 2020;36(3):640-647. doi:
10.1016/j.arthro.2019.10.020PubMedGoogle ScholarCrossref 221.Mu
X, Wei
J, Wang
C,
et al. Intravenous administration of tranexamic acid significantly reduces visible and hidden blood loss compared with its topical administration for double-segment posterior lumbar interbody fusion: a single-center, placebo-controlled, randomized trial.
World Neurosurg. 2019;122:e821-e827. doi:
10.1016/j.wneu.2018.10.154
PubMedGoogle ScholarCrossref 222.Opoku-Anane
J, Vargas
MV, Marfori
CQ, Moawad
G, Maasen
MS, Robinson
JK. Intraoperative tranexamic acid to decrease blood loss during myomectomy: a randomized, double-blind, placebo-controlled trial.
Am J Obstet Gynecol. 2020;223(3):413.e1-413.e7. doi:
10.1016/j.ajog.2020.02.019
PubMedGoogle ScholarCrossref 223.Rowell
SE, Meier
EN, McKnight
B,
et al. Effect of out-of-hospital tranexamic acid vs placebo on 6-month functional neurologic outcomes in patients with moderate or severe traumatic brain injury.
JAMA. 2020;324(10):961-974. doi:
10.1001/jama.2020.8958
PubMedGoogle ScholarCrossref 226.Xu
X, Jiang
J, Liu
W, Li
X, Lu
H. Application of thromboelastography to evaluate the effect of different routes administration of tranexamic acid on coagulation function in total hip arthroplasty.
J Orthop Surg Res. 2019;14(1):430. doi:
10.1186/s13018-019-1497-y
PubMedGoogle ScholarCrossref 228.Zhou
KD, Wang
HY, Wang
Y, Liu
ZH, He
C, Feng
JM. Is topical or intravenous tranexamic acid preferred in total hip arthroplasty? a randomized, controlled, noninferiority clinical trial.
PLoS One. 2018;13(10):e0204551. doi:
10.1371/journal.pone.0204551
PubMedGoogle Scholar 229.Zhou
XD, Zhang
Y, Jiang
LF,
et al. Efficacy and safety of tranexamic acid in intertrochanteric fractures: a single-blind randomized controlled trial.
Orthop Surg. 2019;11(4):635-642. doi:
10.1111/os.12511
PubMedGoogle ScholarCrossref 231.Yates
J, Perelman
I, Khair
S,
et al. Exclusion criteria and adverse events in perioperative trials of tranexamic acid: a systematic review and meta-analysis.
Transfusion. 2019;59(2):806-824. doi:
10.1111/trf.15030
PubMedGoogle ScholarCrossref 232.Franchini
M, Mengoli
C, Cruciani
M,
et al. Safety and efficacy of tranexamic acid for prevention of obstetric haemorrhage: an updated systematic review and meta-analysis.
Blood Transfus. 2018;16(4):329-337. doi:
10.2450/2018.0026-18PubMedGoogle Scholar